Bharatbook.com added a new report on "Opportunities in Human Embryonic Stem Cell (hESC) Products" which gives the development of human embryonic stem cell products.
Online PR News – 17-November-2009 – – Opportunities in Human Embryonic Stem Cell (hESC) Products
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body, providing tremendous therapeutic potential. Human ESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of primate embryonic stem cells occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow human embryonic stem cells derived from human blastocysts. ( http://www.bharatbook.com/Market-Research-Reports/Opportunities-in-Human-Embryonic-Stem-Cell-hESCProducts.html )
As a result of these significant accomplishments at the University of Wisconsin, the Wisconsin Alumni Research Foundation (WARF) filed a series of landmark patents that have affected the intellectual property landscape ever since. These “composition of matter” patents concerning primate embryonic stem cells are controversial because they are so broad that they cover all human embryonic stem cell lines in the United States, not just the specific stem cell lines developed by James Thompson.
Since this time, WARF has been the major “gatekeeper” determining which research product companies have been allowed to conduct research and create commercial products using hESCs. WARF has also been in control of what pharmaceutical companies have been able to develop hESC therapies. Since obtaining its landmark patents in 1998, WARF has only entered into licensing agreements with 27 commercial partners for its intellectual portfolio related to isolating and differentiating hESCs, of which only 15 have been disclosed. 300 academic laboratories have also received agreements for using the technology without charge.
This market report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies that want enter the product area.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/Market-Research-Reports/Opportunities-in-Human-Embryonic-Stem-Cell-hESCProducts.html
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: http://twitter.com/3bbharatbook